ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2088

Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020
Abstract Number: 2089

Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
Abstract Number: 2090

Don’t Throw Out X-Rays! Radiographic Osteoarthritis Severity is Prognostic for Onset of Frequent Knee Pain
Abstract Number: 2091

Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
Abstract Number: 2092

Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study
Abstract Number: 2093

Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-Matched Retrospective Cohort Analysis
Abstract Number: 2094

Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust
Abstract Number: 2095

Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)
Abstract Number: 2096

Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
Abstract Number: 2097

Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
Abstract Number: 2098

Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Abstract Number: 2099

Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
Abstract Number: 2100

Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort
Abstract Number: 2101

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Abstract Number: 2102

Construct Validity of the Six-Minute Walk Test in Knee Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].